C1R-sB7 (ATCC® CRL-2370™)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transforme

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Homo sapiens, human
Cell Type B lymphoblast; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Culture Properties mixed; semi-attached
Biosafety Level 2 Cells contain Herpesvirus
Applications
It secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene.
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7).
B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens.
C1R was derived from Hmy.
Derivation
C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement.
Genes Expressed
Secretes HLA B7 but does not express surface HLA B7
Comments
C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement.
C1R-sB7 has been a reference standard in International Workshops on soluble HLA.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by transferring floating cells to additional flasks.
Attached cells may be subcultured by scraping.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Name of Depositor F Grumet
Year of Origin 1988
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967

Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968

Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
MSDS
MSDS
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967

Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968

Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956